Exolitus

Executive Summary

Exolitus, founded in 2018 and headquartered in Vienna, is a pre-clinical stage biotechnology company specializing in exosome-based therapeutics and cosmeceuticals. The company manufactures exosomes for drug delivery and cosmetic applications, while also providing research tools and services to the scientific community. Despite limited public financial data, Exolitus occupies a niche at the intersection of advanced drug delivery and high-growth cosmeceutical markets. The company's dual focus on therapeutics and research tools provides multiple revenue pathways, though its pre-clinical status implies significant development risk. Exolitus aims to leverage the natural targeting capabilities of exosomes for precise drug delivery, potentially improving efficacy and reducing side effects compared to conventional methods.

Upcoming Catalysts (preview)

• Q3 2026First preclinical proof-of-concept data for lead therapeutic exosome candidate70% success
• Q4 2026Strategic partnership or licensing deal for cosmeceutical exosome products60% success
• Q2 2026Securing seed or Series A financing to advance pipeline50% success